
## Paul T Maruff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5720909/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical and Blood Biomarker Trajectories after Concussion: New Insights from a Longitudinal Pilot Study of Professional Flat-Track Jockeys. Journal of Neurotrauma, 2023, 40, 52-62.	1.7	6
2	Deep Generative Medical Image Harmonization for Improving Crossâ€6ite Generalization in Deep Learning Predictors. Journal of Magnetic Resonance Imaging, 2022, 55, 908-916.	1.9	38
3	Using health check data to investigate cognitive function in Aboriginal and Torres Strait Islanders living with diabetes in the Torres Strait, Australia. Endocrinology, Diabetes and Metabolism, 2022, 5, e00297.	1.0	3
4	Elucidating the association between depression, anxiety, and cognition in middle-aged adults: Application of dimensional and categorical approaches. Journal of Affective Disorders, 2022, 296, 559-566.	2.0	10
5	No Influence of Age-Related Hearing Loss on Brain Amyloid-β. Journal of Alzheimer's Disease, 2022, 85, 359-367.	1.2	6
6	A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects. Journal of Psychopharmacology, 2022, , 026988112110589.	2.0	6
7	Association of <i>BDNF</i> Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	4.5	15
8	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	1.2	5
9	The relationship between cognitive engagement and better memory in midlife. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12278.	1.2	3
10	Cardiovascular Risk Associated with Poorer Memory in Middle-Aged Adults from the Healthy Brain Project. Journal of Alzheimer's Disease, 2022, , 1-11.	1.2	3
11	A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mildâ€toâ€moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12273.	1.8	3
12	Gender moderates the association between chronic academic stress with top-down and bottom-up attention. Attention, Perception, and Psychophysics, 2022, 84, 383-395.	0.7	6
13	Association of Neighborhood-Level Socioeconomic Measures With Cognition and Dementia Risk in Australian Adults. JAMA Network Open, 2022, 5, e224071.	2.8	20
14	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. Science Advances, 2022, 8, eabm5667.	4.7	6
15	Within subject rise in serum TNFα to IL-10 ratio is associated with poorer attention, decision-making and working memory in jockeys. Comprehensive Psychoneuroendocrinology, 2022, 10, 100131.	0.7	5
16	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF Aβ42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	1.5	5
17	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience, 2022, 44, 1807-1823.	2.1	19
18	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβâ^' and Aβ+ Older Adults. Neurology, 2022, 98, e1704-e1715.	1.5	4

#	Article	IF	CITATIONS
19	Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2022, 36, 185-191.	0.6	1
20	Interactive Effects of the BDNF Val66Met Polymorphism and Posttraumatic Stress Disorder on Cognition in U.S. Military Veterans. Psychoneuroendocrinology, 2022, , 105820.	1.3	4
21	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	1.2	7
22	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	1.8	5
23	Association of Î2-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.5	34
24	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnestic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.2	3
25	Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study. Brain, Behavior, and Immunity, 2021, 91, 784-787.	2.0	6
26	Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia. Neuropsychopharmacology, 2021, 46, 1145-1151.	2.8	14
27	The Brain Chart of Aging: Machineâ€learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. Alzheimer's and Dementia, 2021, 17, 89-102.	0.4	92
28	Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12207.	1.2	3
29	Learning deficit in cognitively normal APOE ε4 carriers with LOW βâ€amyloid. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12136.	1.2	7
30	<i>BDNF</i> VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. Genes, Brain and Behavior, 2021, 20, e12724.	1.1	14
31	Visual Memory Deficits in Middle-Aged APOE ɛ4 Homozygotes Detected Using Unsupervised Cognitive Assessments. Journal of Alzheimer's Disease, 2021, 79, 1563-1573.	1.2	4
32	SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	1.2	5
33	Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer's disease. Nature Communications, 2021, 12, 721.	5.8	67
34	The impact of the wake maintenance zone on attentional capacity, physiological drowsiness, and subjective task demands during sleep deprivation. Journal of Sleep Research, 2021, 30, e13312.	1.7	6
35	Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Translational Psychiatry, 2021, 11, 205.	2.4	18
36	Sleep symptomatology is associated with greater subjective cognitive concerns: findings from the community-based Healthy Brain Project. Sleep, 2021, 44, .	0.6	8

#	Article	IF	CITATIONS
37	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	1.8	8
38	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. Drug Discovery Today, 2021, 26, 1330-1336.	3.2	3
39	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	1.0	2
40	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	1.2	59
41	Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 1039-1052.	1.2	2
42	An Online, Person-Centered, Risk Factor Management Program to Prevent Cognitive Decline: Protocol for A Prospective Behavior-Modification Blinded Endpoint Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1603-1622.	1.2	5
43	Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer's Disease, 2021, 83, 915-925.	1.2	8
44	A Paradox in Digital Memory Assessment: Increased Sensitivity With Reduced Difficulty. Frontiers in Digital Health, 2021, 3, 780303.	1.5	2
45	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral AÎ <sup>2</sup> -Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience, 2021, 13, 744872.	1.7	17
46	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. Nature Communications, 2021, 12, 7065.	5.8	38
47	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 800126.	1.7	19
48	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Scientific Reports, 2021, 11, 23788.	1.6	16
49	Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis Journal, 2020, 26, 109-113.	1.4	10
50	Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 55-65.	0.8	10
51	The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, 2020, 28, 3081-3091.	1.0	14
52	Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. Journal of Alzheimer's Disease, 2020, 73, 683-693.	1.2	0
53	Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan. NeuroImage, 2020, 208, 116450.	2.1	260
54	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer's and Dementia, 2020, 16, 552-560.	0.4	55

#	Article	IF	CITATIONS
55	Influence of Comorbidity of Cerebrovascular Disease and Amyloid-Î <sup>2</sup> on Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 897-907.	1.2	21
56	Assessing the utility of a virtual-reality neuropsychological test battery, â€~CONVIRT', in detecting alcohol-induced cognitive impairment. Behavior Research Methods, 2020, 53, 1115-1123.	2.3	6
57	Acceptability and Usability of Computerized Cognitive Assessment Among Australian Indigenous Residents of the Torres Strait Islands. Archives of Clinical Neuropsychology, 2020, 35, 1288-1302.	0.3	3
58	Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	18
59	Validation of online functional measures in cognitively impaired older adults. Alzheimer's and Dementia, 2020, 16, 1426-1437.	0.4	20
60	The impact of structured sleep schedules prior to an in-laboratory study: Individual differences in sleep and circadian timing. PLoS ONE, 2020, 15, e0236566.	1.1	5
61	Evaluation of the effect of Cooled HaEmodialysis on Cognitive function in patients suffering with end-stage KidnEy Disease (E-CHECKED): feasibility randomised control trial protocol. Trials, 2020, 21, 820.	0.7	6
62	Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture. Nature Communications, 2020, 11, 4799.	5.8	110
63	Association of deficits in short-term learning and AÎ <sup>2</sup> and hippocampal volume in cognitively normal adults. Neurology, 2020, 95, e2577-e2585.	1.5	31
64	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	1.8	5
65	Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1057-1065.	1.2	27
66	Unsupervised assessment of cognition in the Healthy Brain Project: Implications for webâ€based registries of individuals at risk for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12043.	1.8	34
67	Keith Wesnes: Psychopharmacology pioneer. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12087.	1.2	Ο
68	Development of a new virtual reality test of cognition: assessing the test-retest reliability, convergent and ecological validity of CONVIRT. BMC Psychology, 2020, 8, 61.	0.9	14
69	Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer〙s disease after a 27-month delay interval. Alzheimer's Research and Therapy, 2020, 12, 31.	3.0	6
70	Assessing the Long-Term Impact of Concussion upon Cognition: A 5-Year Prospective Investigation. Archives of Clinical Neuropsychology, 2020, 35, 482-490.	0.3	8
71	MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14 468 individuals worldwide. Brain, 2020, 143, 2312-2324.	3.7	183
72	The Effect of Hearing Aid Use on Cognition in Older Adults: Can We Delay Decline or Even Improve Cognitive Function?. Journal of Clinical Medicine, 2020, 9, 254.	1.0	75

#	Article	IF	CITATIONS
73	Personality factors and cerebral glucose metabolism in community-dwelling older adults. Brain Structure and Function, 2020, 225, 1511-1522.	1.2	3
74	Comorbidity of Cerebrovascular andÂAlzheimer's Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	1.2	4
75	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. Archives of Clinical Neuropsychology, 2019, 34, 585-598.	0.3	23
76	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
77	F83. Differential Effects of Ketamine on Mood Symptoms and Cognitive Function in MDD and PTSD. Biological Psychiatry, 2019, 85, S244-S245.	0.7	0
78	SuperAging: Current findings yield future challenges—A response to Rogalski and Goldberg. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 562-563.	1.2	0
79	Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis. Frontiers in Neurology, 2019, 10, 976.	1.1	3
80	The Potential of a Narrative and Creative Arts Approach to Enhance Transition Outcomes for Indigenous Australians Following Traumatic Brain Injury. Brain Impairment, 2019, 20, 160-170.	0.5	11
81	T26. CLINICAL OUTCOME ASSESSMENTS FOR TRIALS IN COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S213-S213.	2.3	0
82	The Effect of Cochlear Implants on Cognitive Function in Older Adults: Initial Baseline and 18-Month Follow Up Results for a Prospective International Longitudinal Study. Frontiers in Neuroscience, 2019, 13, 789.	1.4	67
83	Indigenous traumatic brain injury research: responding to recruitment challenges in the hospital environment. BMC Medical Research Methodology, 2019, 19, 172.	1.4	3
84	Rates of age―and amyloid βâ€associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	1.2	21
85	Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	1.5	23
86	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
87	COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
88	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	0.8	18
89	Computerized cognitive performance assessments in the Brooklyn Cognitive Impairments in Health Disparities Pilot Study. Alzheimer's and Dementia, 2019, 15, 1420-1426.	0.4	5
90	A Qualitative Study on the Transition Support Needs of Indigenous Australians Following Traumatic Brain Injury. Brain Impairment, 2019, 20, 137-159.	0.5	18

#	Article	IF	CITATIONS
91	Use of Cognition to Guide Decisions About the Safety and Efficacy of Drugs in Early-Phase Clinical Trials. Handbook of Behavioral Neuroscience, 2019, , 219-227.	0.7	0
92	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
93	Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir. Journal of NeuroVirology, 2019, 25, 22-31.	1.0	1
94	The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis. Biological Psychiatry, 2019, 86, 35-44.	0.7	23
95	Reduced professional efficacy is associated with a blunted salivary alpha-amylase awakening response. Physiology and Behavior, 2019, 199, 292-299.	1.0	6
96	Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults Neuropsychology, 2019, 33, 964-974.	1.0	17
97	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden. Translational Psychiatry, 2018, 8, 47.	2.4	92
98	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13
99	The Transition from Hospital to Home: Protocol for a Longitudinal Study of Australian Aboriginal and Torres Strait Islander Traumatic Brain Injury (TBI). Brain Impairment, 2018, 19, 246-257.	0.5	8
100	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
101	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. Journal of Alzheimer's Disease, 2018, 61, 1589-1598.	1.2	44
102	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports, 2018, 8, 2034.	1.6	31
103	Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 488.	4.5	70
104	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. Journal of Affective Disorders, 2018, 229, 269-274.	2.0	27
105	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. Alzheimer Disease and Associated Disorders, 2018, 32, 190-196.	0.6	19
106	Cognitive Function Before and After Left Heart Catheterization. Journal of the American Heart Association, 2018, 7, .	1.6	17
107	Trajectories of depressive and anxiety symptoms in older adults: a 6â€year prospective cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 405-413.	1.3	20
108	Apolipoprotein E gene polymorphism, trauma burden, and posttraumatic stress symptoms in U.S. military veterans: Results from the National Health and Resilience in Veterans Study. Depression and Anxiety, 2018, 35, 168-177.	2.0	20

#	ARTICLE	IF	CITATIONS
109	O1â€04â€01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAY RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY. Alzheimer's and Dementia, 2018, 14, P223.	S: 0.4	0
110	O1â€04â€04: VALIDATION OF ONLINE DATA FROM IDEAS PARTICIPANTS WITH MCI AND AD USING THE BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P225.	0.4	0
111	Total Sleep Time Interacts With Age to Predict Cognitive Performance Among Adults. Journal of Clinical Sleep Medicine, 2018, 14, 1587-1594.	1.4	16
112	O1â€10â€01: EFFECTS OF BDNF VAL66MET ON MEMORY DECLINE AND CSF BIOMARKERS IN PRECLINICAL, PRODROMAL AND CLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P242.	0.4	0
113	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	1.2	27
114	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	1.7	16
115	Incidence of emergency department presentations for traumatic brain injury in Indigenous and non-Indigenous residents aged 15–64 over the 9-year period 2007–2015 in North Queensland, Australia. Injury Epidemiology, 2018, 5, 40.	0.8	22
116	Online study partnerâ€reported cognitive decline in the Brain Health Registry. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 565-574.	1.8	29
117	Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research and Therapy, 2018, 10, 107.	3.0	80
118	Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018. Acta Anaesthesiologica Scandinavica, 2018, 62, 1473-1480.	0.7	19
119	The wake maintenance zone shows task dependent changes in cognitive function following one night without sleep. Sleep, 2018, 41, .	0.6	25
120	Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Translational Psychiatry, 2018, 8, 238.	2.4	49
121	The relationship between depression and cognitive function in adults with cardiovascular risk: Evidence from a randomised attention-controlled trial. PLoS ONE, 2018, 13, e0203343.	1.1	13
122	Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	1.2	19
123	Sex, amyloid, and <i>APOE</i> ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.4	169
124	Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 573-582.	1.2	54
125	Effect of <i>BDNF</i> Val66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	2.8	25
126	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence, 2018, 70, 22-29.	1.6	13

#	Article	IF	CITATIONS
127	Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 977-988.	1.2	15
128	Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018. British Journal of Anaesthesia, 2018, 121, 1005-1012.	1.5	420
129	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. Neurobiology of Aging, 2018, 70, 170-179.	1.5	14
130	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study Psychological Assessment, 2018, 30, 1308-1316.	1.2	5
131	Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 2017, 32, 455-463.	1.3	49
132	Cognitive impairment and decline in cognitively normal older adults with high amyloidâ€Î²: A metaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 108-121.	1.2	131
133	APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2017, 57, 411-422.	1.2	9
134	Preliminary evidence concerning the pattern and magnitude of cognitive dysfunction in major depressive disorder using cogstate measures. Journal of Affective Disorders, 2017, 218, 82-85.	2.0	18
135	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	1.2	35
136	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 147-155.	1.2	28
137	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. Journal of Alzheimer's Disease, 2017, 58, 193-201.	1.2	12
138	Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging. Archives of Clinical Neuropsychology, 2017, 32, 142-154.	0.3	51
139	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 2017, 7, 9766.	1.6	59
140	Chronic work stress and decreased vagal tone impairs decision making and reaction time in jockeys. Psychoneuroendocrinology, 2017, 84, 151-158.	1.3	35
141	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. International Psychogeriatrics, 2017, 29, 1825-1834.	0.6	21
142	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8â€OH quinoline in Alzheimer's disease: The PBT2â€204 IMAGINE study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 622-635.	1.8	59
143	Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	1.2	19
144	Annual baseline drift in professional rugby league players. British Journal of Sports Medicine, 2017, 51, A46.2-A46.	3.1	0

#	Article	IF	CITATIONS
145	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. Alzheimer's and Dementia, 2017, 13, 388-398.	0.4	23
146	Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.1	32
147	Annual Baseline Drift in Professional Rugby League Players. Medicine and Science in Sports and Exercise, 2017, 49, 219-220.	0.2	0
148	[O2–16–02]: ACCEPTABILITY, USABILITY, VALIDITY AND SENSITIVITY OF COGNITION ASSESSED IN UNSUPERVISED SETTINGS. Alzheimer's and Dementia, 2017, 13, P596.	0.4	2
149	[O3–06–06]: VALIDATION OF STUDY PARTNERâ€REPORTED OUTCOMES COLLECTED ONLINE USING THE BR HEALTH REGISTRY. Alzheimer's and Dementia, 2017, 13, P913.	AIN 0.4	1
150	Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain, 2017, 140, 2112-2119.	3.7	213
151	Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2017, 31, 271-277.	0.6	3
152	Resting-State Cardiac Workload is Related to Both Increased Neocortical Aggregation of Amyloid-β and Relative Impairments in Spatial Working Memory in Pre-Clinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 127-131.	1.2	3
153	The Incidence Of Concussion And The Risk Of Subsequent Concussions In Professional Rugby League. Medicine and Science in Sports and Exercise, 2016, 48, 529.	0.2	Ο
154	Prevalence of Dementia 7.5 Years after Coronary Artery Bypass Graft Surgery. Anesthesiology, 2016, 125, 62-71.	1.3	135
155	Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. Anesthesiology, 2016, 124, 353-361.	1.3	105
156	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Movement Disorders, 2016, 31, 1049-1054.	2.2	28
157	Aβ-related memory decline in <i>APOE</i> Îμ4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.5	37
158	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. British Journal of Cancer, 2016, 114, 956-964.	2.9	38
159	β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	0.6	25
160	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	1.1	14
161	Nonvascular retinal imaging markers of preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 169-178.	1.2	82
162	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain, 2016, 139, 2766-2777.	3.7	70

#	Article	IF	CITATIONS
163	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.5	26
164	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurology, The, 2016, 15, 1044-1053.	4.9	175
165	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. Acta Neuropathologica, 2016, 132, 377-389.	3.9	40
166	The Relationship between Sleep Quality and Brain Amyloid Burden. Sleep, 2016, 39, 1063-1068.	0.6	123
167	A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clinical Infectious Diseases, 2016, 63, 687-693.	2.9	63
168	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	1.2	72
169	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 796-804.	0.4	135
170	Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. Alzheimer's and Dementia, 2016, 12, 454-458.	0.4	55
171	Spatial sequence memory and spatial error monitoring in the Groton Maze Learning Task (GMLT): A validation study of GMLT sub-measures in healthy children. Child Neuropsychology, 2016, 22, 837-852.	0.8	13
172	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-5.	1.5	39
173	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. British Journal of Nutrition, 2015, 114, 1683-1693.	1.2	5
174	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease Neuropsychology, 2015, 29, 571-581.	1.0	43
175	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
176	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	1.2	28
177	Preexisting Cognitive Impairment Is Associated with Postoperative Cognitive Dysfunction after Hip Joint Replacement Surgery. Anesthesiology, 2015, 122, 1224-1234.	1.3	189
178	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	1.1	22
179	The nature and rate of cognitive maturation from late childhood to adulthood. Frontiers in Psychology, 2015, 6, 704.	1.1	47
180	O3-03-04: Characteristics of the neighborhood built environment are associated with MRI brain volumetric and amyloid beta burden measures: Findings from the australian imaging, biomarkers, and lifestyle (AIBL) study. , 2015, 11, P223-P225.		0

#	Article	IF	CITATIONS
181	Amyloid-beta and depression in healthy older adults: A systematic review. Australian and New Zealand Journal of Psychiatry, 2015, 49, 36-46.	1.3	66
182	APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	1.5	75
183	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.3	40
184	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ε4 status. Neuropsychologia, 2015, 75, 411-419.	0.7	27
185	Long-term plasticity in adult somatosensory cortex: functional reorganization after surgical removal of an arteriovenous malformation. Neurocase, 2015, 21, 618-627.	0.2	1
186	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of Aging, 2015, 36, 1231-1238.	1.5	71
187	A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research, 2015, 164, 136-142.	1.1	59
188	Amyloid-β, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psychiatry, 2015, 72, 284.	6.0	160
189	AZD6280, a Novel Partial Î <sup>3</sup> -Aminobutyric Acid A Receptor Modulator, Demonstrates a Pharmacodynamically Selective Effect Profile in Healthy Male Volunteers. Journal of Clinical Psychopharmacology, 2015, 35, 22-33.	0.7	19
190	Comparison of Cognitive Performance on the Cogstate Brief Battery When Taken In-Clinic, In-Group, and Unsupervised. Clinical Neuropsychologist, 2015, 29, 542-558.	1.5	53
191	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. Age and Ageing, 2015, 44, 1012-1019.	0.7	31
192	A randomized controlled trial of light versus deep propofol sedation for elective outpatient colonoscopy: recall, procedural conditions, and recovery. Canadian Journal of Anaesthesia, 2015, 62, 1169-1178.	0.7	37
193	Disruption of cholinergic neurotransmission exacerbates AÎ <sup>2</sup> -related cognitive impairment in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2709-2715.	1.5	59
194	Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress. Stress and Health, 2015, 31, 115-123.	1.4	80
195	APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Molecular Psychiatry, 2015, 20, 1322-1328.	4.1	105
196	Understanding the importance of cognitive dysfunction and cognitive change in major depressive disorder. , 2015, , 15-29.		3
197	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). , 2015, , .		2
198	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	1.1	75

#	Article	IF	CITATIONS
199	The Development of Associate Learning in School Age Children. PLoS ONE, 2014, 9, e101750.	1.1	7
200	A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H <sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 47-58.	0.7	95
201	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. British Journal of Psychiatry, 2014, 204, 400-401.	1.7	29
202	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
203	Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical Endocrinology, 2014, 81, 621-628.	1.2	26
204	Behavior at the Choice Point: Decision Making in Hidden Pathway Maze Learning. Neuropsychology Review, 2014, 24, 514-536.	2.5	9
205	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 120-127.	0.9	58
206	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics, 2014, 26, 543-554.	0.6	37
207	Monitoring change requires a rethink of assessment practices in voice and speech. Logopedics Phoniatrics Vocology, 2014, 39, 56-61.	0.5	37
208	Detecting Cognitive Impairment After Concussion: Sensitivity of Change From Baseline and Normative Data Methods Using the CogSport/Axon Cognitive Test Battery. Archives of Clinical Neuropsychology, 2014, 29, 432-441.	0.3	94
209	The central nervous system effects of the partial <scp>GABA</scp> â€ <scp>A</scp> î± <sub>2,3</sub> â€selective receptor modulator <scp>AZD7325</scp> in comparison with lorazepam in healthy males. British Journal of Clinical Pharmacology, 2014, 78, 1298-1314.	1.1	31
210	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. International Psychogeriatrics, 2014, 26, 1737-1746.	0.6	9
211	Microdosing of scopolamine as a "cognitive stress testâ€: Rationale and test of a very low dose in an atâ€risk cohort of older adults. Alzheimer's and Dementia, 2014, 10, 262-267.	0.4	27
212	Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. Computers in Human Behavior, 2014, 30, 199-205.	5.1	35
213	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain, 2014, 137, 221-231.	3.7	182
214	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.5	58
215	Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.4	66
216	The impact of task automaticity on speech in noise. Speech Communication, 2014, 65, 1-8.	1.6	23

#	Article	IF	CITATIONS
217	Plasma Amyloid-β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. Journal of Alzheimer's Disease, 2014, 40, 95-104.	1.2	41
218	Amyloid-β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	1.2	63
219	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics, 2014, 15, S11.	1.2	67
220	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. Journal of Alzheimer's Disease, 2014, 40, 551-561.	1.2	10
221	P4-293: COMPARISON OF THREE NORMATIVE DATA CORRECTION APPROACHES: A CROSS-SECTIONAL EVALUATION IN THE AIBL STUDY. , 2014, 10, P891-P892.		2
222	Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults. Psychopharmacology, 2013, 228, 673-683.	1.5	15
223	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychology, 2013, 1, 30.	0.9	153
224	Predicting Alzheimer disease with βâ€∎myloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	2.8	194
225	Aβ amyloid, cognition, and <i>APOE</i> genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.4	51
226	Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European Neuropsychopharmacology, 2013, 23, 1373-1382.	0.3	69
227	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
228	Massed versus spaced visuospatial memory in cognitively healthy young and older adults. , 2013, 9, S32-S38.		8
229	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	4.9	1,738
230	BDNF Val66Met, $A\hat{I}^2$ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	1.5	109
231	A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. Addiction, 2013, 108, 1107-1114.	1.7	20
232	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-β. Journal of Alzheimer's Disease, 2013, 34, 861-871.	1.2	42
233	Lack of reliable evidence for a distinctive ε4â~'related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. Brain, 2013, 136, 2201-2216.	3.7	28
234	The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. International Journal of Neuropsychopharmacology, 2013, 16, 721-731.	1.0	84

#	Article	IF	CITATIONS
235	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). Archives of Clinical Neuropsychology, 2013, 28, 320-330.	0.3	90
236	Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women. Menopause, 2013, 20, 1020-1026.	0.8	17
237	The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI. International Psychogeriatrics, 2013, 25, 1667-1677.	0.6	24
238	Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-β: Prodromal Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 33, 1167-1176.	1.2	34
239	Disentangling component learning and executive processes in hidden pathway maze learning in children: A process-based approach. Child Neuropsychology, 2013, 19, 588-600.	0.8	8
240	Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease Neuropsychology, 2013, 27, 322-332.	1.0	33
241	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-β. Journal of Alzheimer's Disease, 2013, 33, 675-679.	1.2	62
242	The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H <sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer's Disease: A Preliminary Investigation. Current Alzheimer Research, 2013, 10, 240-251.	0.7	64
243	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 853-863.	0.8	13
244	Preexisting Cognitive Impairment and Mild Cognitive Impairment in Subjects Presenting for Total Hip Joint Replacement. Survey of Anesthesiology, 2012, 56, 119-120.	0.1	0
245	Preexisting Cognitive Impairment and Mild Cognitive Impairment in Subjects Presenting for Total Hip Joint Replacement. Survey of Anesthesiology, 2012, 56, 18-19.	0.1	1
246	Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine. Postgraduate Medicine, 2012, 124, 7-15.	0.9	58
247	Preliminary Data on the Effect of Culture on the Assessment of Alzheimer's Disease-Related Verbal Memory Impairment with the International Shopping List Test. Archives of Clinical Neuropsychology, 2012, 27, 136-147.	0.3	14
248	Barriers to Repeated Assessment of Verbal Learning and Memory: A Comparison of International Shopping List Task and Rey Auditory Verbal Learning Test on Build-Up of Proactive Interference. Archives of Clinical Neuropsychology, 2012, 27, 790-795.	0.3	6
249	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. Neurology, 2012, 79, 1645-1652.	1.5	96
250	A processâ€based approach to characterizing the effect of acute alprazolam challenge on visual paired associate learning and memory in healthy older adults. Human Psychopharmacology, 2012, 27, 549-558.	0.7	9
251	Depressed Older Patients With the Atypical Features of Interpersonal Rejection Sensitivity and Reversed-Vegetative Symptoms are Similar to Younger Atypical Patients. American Journal of Geriatric Psychiatry, 2012, 20, 622-634.	0.6	5
252	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 345-358.	0.8	111

#	Article	IF	CITATIONS
253	Computerized cognitive remediation training for schizophrenia: An open label, multi-site, multinational methodology study. Schizophrenia Research, 2012, 139, 87-91.	1.1	77
254	Mild Worry Symptoms Predict Decline in Learning and Memory in Healthy Older Adults: A 2-Year Prospective Cohort Study. American Journal of Geriatric Psychiatry, 2012, 20, 266-275.	0.6	86
255	Intraindividual cognitive decline using a brief computerized cognitive screening test. Alzheimer's and Dementia, 2012, 8, 95-104.	0.4	66
256	Factors associated with continued solvent use in Indigenous petrol sniffers following treatment. Drug and Alcohol Review, 2012, 31, 40-46.	1.1	13
257	Clinical characteristics of 150 consecutive fibromyalgia patients attending an Australian public hospital clinic. International Journal of Rheumatic Diseases, 2012, 15, 348-357.	0.9	13
258	Cognitive recovery during and after treatment for volatile solvent abuse. Drug and Alcohol Dependence, 2011, 118, 180-185.	1.6	28
259	Reliability, Stability, and Sensitivity to Change and Impairment in Acoustic Measures of Timing and Frequency. Journal of Voice, 2011, 25, 137-149.	0.6	58
260	Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study. Maturitas, 2011, 70, 307-311.	1.0	42
261	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. , 2011, 7, 127-132.		35
262	A webâ€based normative data tool for assessing cognitive performance in healthy older Australians. Medical Journal of Australia, 2011, 194, S12-4.	0.8	3
263	Neuropsychological problems and alcohol availability appear to be key factors in continued heavy alcohol use by Aboriginal Australians. Medical Journal of Australia, 2011, 194, 50-51.	0.8	2
264	Criterion and Construct Validity of the CogState Schizophrenia Battery in Japanese Patients with Schizophrenia. PLoS ONE, 2011, 6, e20469.	1.1	34
265	Detecting Subtle Changes in Visuospatial Executive Function and Learning in the Amnestic Variant of Mild Cognitive Impairment. PLoS ONE, 2011, 6, e21688.	1.1	20
266	Anesthesiology Must Play a Greater Role in Patients with Alzheimer's Disease. Anesthesia and Analgesia, 2011, 112, 1242-1245.	1.1	20
267	Postoperative Cognitive Dysfunction Is Independent of Type of Surgery and Anesthetic. Anesthesia and Analgesia, 2011, 112, 1179-1185.	1.1	340
268	The needle has been blunt for 20 years. International Psychogeriatrics, 2011, 23, 330-331.	0.6	0
269	Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease. International Psychogeriatrics, 2011, 23, 1376-1385.	0.6	14
270	Examining the nature of impairment in visual paired associate learning in amnestic mild cognitive impairment Neuropsychology, 2011, 25, 752-762.	1.0	25

#	Article	lF	CITATIONS
271	Episodic Memory Decline Predicts Cortical Amyloid Status in Community-Dwelling Older Adults. Journal of Alzheimer's Disease, 2011, 27, 627-637.	1.2	34
272	Similar profile of cognitive impairment and recovery for Aboriginal Australians in treatment for episodic or chronic alcohol use. Addiction, 2011, 106, 1419-1426.	1.7	10
273	Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology, 2011, 218, 513-524.	1.5	36
274	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 87-89.	2.0	57
275	The effect of acute increase in urge to void on cognitive function in healthy adults. Neurourology and Urodynamics, 2011, 30, 183-187.	0.8	26
276	Neuropsychological changes and treatment response in severe depression. British Journal of Psychiatry, 2011, 198, 115-122.	1.7	57
277	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. Dementia and Geriatric Cognitive Disorders, 2011, 31, 173-178.	0.7	115
278	Sensitivity and Test-Retest Reliability of the International Shopping List Test in Assessing Verbal Learning and Memory in Mild Alzheimer's Disease. Archives of Clinical Neuropsychology, 2011, 26, 412-424.	0.3	39
279	Spatial memory and executive functions in children. Child Neuropsychology, 2011, 17, 599-615.	0.8	12
280	Understanding failure of visual paired associate learning in amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1069-1078.	0.8	13
281	Preexisting Cognitive Impairment and Mild Cognitive Impairment in Subjects Presenting for Total Hip Joint Replacement. Anesthesiology, 2011, 114, 1297-1304.	1.3	76
282	HIV and Age Do Not Substantially Interact in HIV-Associated Neurocognitive Impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 83-89.	0.9	37
283	HIV and age do not substantially interact in HIV-associated neurocognitive impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 83-9.	0.9	28
284	Perception of alcohol intoxication shows acute tolerance while executive functions remain impaired Experimental and Clinical Psychopharmacology, 2010, 18, 329-339.	1.3	44
285	Assessment of cognition in an adolescent Indigenous population. Australian Psychologist, 2010, 45, 123-131.	0.9	18
286	Use of an acute challenge with dâ€amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology, 2010, 25, 353-358.	0.7	39
287	A comparison of statistical approaches used to evaluate change in cognitive function following pharmacologic challenge: an example with lorazepam. Human Psychopharmacology, 2010, 25, 335-341.	0.7	10
288	Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection. Clinical Microbiology and Infection, 2010, 16, 1579-1584.	2.8	17

#	Article	IF	CITATIONS
289	Evaluation of communication assessment practices during the acute stages post stroke. Journal of Evaluation in Clinical Practice, 2010, 16, 1183-1188.	0.9	47
290	An Examination of Developmental Trajectories for Attention Skills in Children. Australian Educational and Developmental Psychologist, 2010, 27, 76-89.	0.7	1
291	Charles Darwin's Emotional Expression "Experiment―and His Contribution to Modern Neuropharmacology. Journal of the History of the Neurosciences, 2010, 19, 158-170.	0.1	9
292	Acoustic analysis of the effects of sustained wakefulness on speech. Journal of the Acoustical Society of America, 2010, 128, 3747-3756.	0.5	49
293	Evaluation of the Usability of a Brief Computerized Cognitive Screening Test in Older People for Epidemiological Studies. Neuroepidemiology, 2010, 34, 65-75.	1.1	178
294	Assessing Cognition Following Petrol Sniffing for Indigenous Australians. Australian and New Zealand Journal of Psychiatry, 2010, 44, 631-639.	1.3	21
295	SOCIAL COGNITION IN SCHIZOPHRENIA: A QUANTITATIVE REVIEW OF THE LITERATURE. Schizophrenia Research, 2010, 117, 413-414.	1.1	2
296	Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophrenia Research, 2010, 124, 176-182.	1.1	23
297	Natural History of Concussion in Sport. American Journal of Sports Medicine, 2010, 38, 464-471.	1.9	244
298	Reliability of repeated cognitive testing in healthy Indigenous Australian adolescents. Australian Psychologist, 2009, 44, 224-234.	0.9	36
299	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 848-859.	0.8	156
300	Convergent Validity and Effect of Instruction Modification on the Groton Maze Learning Test: A New Measure of Spatial Working Memory and Error Monitoring. International Journal of Neuroscience, 2009, 119, 1137-1149.	0.8	16
301	Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5â€HT <sub>1A</sub> receptor agonist. Human Psychopharmacology, 2009, 24, 437-446.	0.7	32
302	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate reâ€ŧest intervals. Human Psychopharmacology, 2009, 24, 113-121.	0.7	40
303	Methodological improvements in quantifying cognitive change in clinical trials: An example with single-dose administration of donepezil. Journal of Nutrition, Health and Aging, 2009, 13, 268-273.	1.5	18
304	Standardization of pitch-range settings in voice acoustic analysis. Behavior Research Methods, 2009, 41, 318-324.	2.3	53
305	A method for cross-cultural adaptation of a verbal memory assessment. Behavior Research Methods, 2009, 41, 1190-1200.	2.3	60
306	Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex. Archives of Clinical Neuropsychology, 2009, 24, 165-178.	0.3	475

#	Article	IF	CITATIONS
307	Hunger and the perception of the scent of petrol: A potential neurobiological basis for increased risk of petrol inhalation abuse. Addiction Research and Theory, 2009, 17, 518-524.	1.2	2
308	Neurocognitive Function in Attention-Deficit–Hyperactivity Disorder with and Without Comorbid Disruptive Behaviour Disorders. Australian and New Zealand Journal of Psychiatry, 2009, 43, 722-730.	1.3	41
309	Plasma Amyloid $\hat{l}^2$ 42 and Amyloid $\hat{l}^2$ 40 Levels Are Associated With Early Cognitive Dysfunction After Cardiac Surgery. Annals of Thoracic Surgery, 2009, 88, 1426-1432.	0.7	35
310	Differences in Neuropsychological Performance Between Subtypes of Obsessive–Compulsive Disorder. Australian and New Zealand Journal of Psychiatry, 2009, 43, 216-226.	1.3	53
311	Early Cognitive Impairment After Sedation for Colonoscopy: The Effect of Adding Midazolam and/or Fentanyl to Propofol. Anesthesia and Analgesia, 2009, 109, 1448-1455.	1.1	81
312	Increased Anti-saccade Latency Is an Isolated Lingering Abnormality in Sydenham Chorea. Journal of Neuro-Ophthalmology, 2009, 29, 143-145.	0.4	4
313	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 672-687.	0.6	661
314	The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Human Psychopharmacology, 2008, 23, 425-436.	0.7	58
315	Quetiapine augmentation in depressed patients with partial response to antidepressants. Human Psychopharmacology, 2008, 23, 653-660.	0.7	19
316	Comparison of voice acquisition methodologies in speech research. Behavior Research Methods, 2008, 40, 982-987.	2.3	32
317	Differences in motor imagery between children with developmental coordination disorder with and without the combined type of ADHD. Developmental Medicine and Child Neurology, 2008, 50, 608-612.	1.1	42
318	The link between motor impairment level and motor imagery ability in children with developmental coordination disorder. Human Movement Science, 2008, 27, 270-285.	0.6	92
319	Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, 2008, 46, 1688-1697.	0.7	272
320	Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia, 2008, 46, 2476-2484.	0.7	48
321	An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Archives of Clinical Neuropsychology, 2008, 23, 433-445.	0.3	82
322	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Research, 2008, 160, 316-326.	1.7	34
323	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	2.1	81
324	Measuring the mind: assessing cognitive change in clinical drug trials. Expert Review of Clinical Pharmacology, 2008, 1, 471-473.	1.3	18

#	Article	IF	CITATIONS
325	Effect of Treatment with Stimulant Medication on Nonverbal Executive Function and Visuomotor Speed in Children with Attention Deficit/Hyperactivity Disorder (ADHD). Child Neuropsychology, 2008, 14, 211-226.	0.8	41
326	The nature of cognitive complaints in healthy older adults with and without objective memory decline. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 245-257.	0.8	85
327	Large Scale Computerized Concussion Testing: Experience in Thousands of Elite Athletes. Medicine and Science in Sports and Exercise, 2008, 40, S68-S69.	0.2	0
328	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130, 2837-2844.	3.7	739
329	Imaging Â-amyloid burden in aging and dementia. Neurology, 2007, 68, 1718-1725.	1.5	997
330	Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study. European Journal of Endocrinology, 2007, 156, 439-447.	1.9	57
331	Preexisting Cognitive Impairment in Patients Scheduled for Elective Coronary Artery Bypass Graft Surgery. Anesthesia and Analgesia, 2007, 104, 1023-1028.	1.1	105
332	Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review. Psychiatry Research, 2007, 150, 111-121.	1.7	142
333	The influence of different error estimates in the detection of postoperative cognitive dysfunction using reliable change indices with correction for practice effects. Archives of Clinical Neuropsychology, 2007, 22, 249-257.	0.3	20
334	Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study. Contemporary Clinical Trials, 2007, 28, 391-400.	0.8	73
335	Decline in verbal memory in non-demented older adults. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 706-718.	0.8	33
336	Cognitive impairment in Aboriginal people with heavy episodic patterns of alcohol use. Addiction, 2007, 102, 909-915.	1.7	47
337	Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Medicine, 2007, 8, 192-202.	1.0	36
338	Improved cognitive function as a consequence of hepatitis C virus treatment <sup>*</sup> . HIV Medicine, 2007, 8, 520-528.	1.0	55
339	Computerised Tests of Brain Function for Use with Indigenous People. , 2007, , 257-259.		6
340	The Development of Sustained Attention in Children: The Effect of Age and Task Load. Child Neuropsychology, 2006, 12, 205-221.	0.8	177
341	Visuospatial working memory deficits in adolescent onset schizophrenia. Schizophrenia Research, 2006, 87, 223-227.	1.1	15
342	Practice Effects Associated with the Repeated Assessment of Cognitive Function Using the CogState Battery at 10-minute, One Week and One Month Test-retest Intervals. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1095-1112.	0.8	339

#	Article	IF	CITATIONS
343	Detection of Postoperative Cognitive Decline After Coronary Artery Bypass Graft Surgery is Affected by the Number of Neuropsychological Tests in the Assessment Battery. Annals of Thoracic Surgery, 2006, 81, 2097-2104.	0.7	61
344	The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Archives of Clinical Neuropsychology, 2006, 21, 185-194.	0.3	133
345	The influence of different error estimates in the detection of post-operative cognitive dysfunction using reliable change indices with correction for practice effects. Archives of Clinical Neuropsychology, 2006, 21, 421-427.	0.3	31
346	Mild memory impairment in healthy older adults is distinct from normal aging. Brain and Cognition, 2006, 60, 146-155.	0.8	49
347	Does atypical antipsychotic medication improve executive function in schizophrenia?. International Journal of Neuropsychopharmacology, 2006, 9, 629.	1.0	1
348	The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: A meta-analysis. Journal of the International Neuropsychological Society, 2006, 12, 368-82.	1.2	56
349	A Comparison of the Effect of High- and Low-dose Fentanyl on the Incidence of Postoperative Cognitive Dysfunction after Coronary Artery Bypass Surgery in the Elderly. Anesthesiology, 2006, 104, 1137-1145.	1.3	106
350	The sensitivity and specificity of three common statistical rules for the classification of post-operative cognitive dysfunction following coronary artery bypass graft surgery. Acta Anaesthesiologica Scandinavica, 2006, 50, 50-57.	0.7	52
351	Motor, visual and egocentric transformations in children with Developmental Coordination Disorder. Child: Care, Health and Development, 2006, 32, 633-647.	0.8	68
352	Changes in cannabis use and its consequences over 3 years in a remote indigenous population in northern Australia. Addiction, 2006, 101, 696-705.	1.7	37
353	Assessing cognitive function in cancer patients. Supportive Care in Cancer, 2006, 14, 1111-1118.	1.0	120
354	A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam. Psychopharmacology, 2006, 186, 7-17.	1.5	38
355	Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 2006, 30, 1225-1245.	2.9	193
356	Evaluating brain activity in obsessive–compulsive disorder: Preliminary insights from a multivariate analysis. Psychiatry Research - Neuroimaging, 2006, 147, 227-231.	0.9	13
357	The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: A meta-analysis of the current literature. Psychoneuroendocrinology, 2006, 31, 681-691.	1.3	138
358	Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurology, 2006, 6, 42.	0.8	23
359	Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study. Human Psychopharmacology, 2006, 21, 481-488.	0.7	21
360	Cognition in the days following concussion: comparison of symptomatic versus asymptomatic athletes. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 241-245.	0.9	155

#	Article	IF	CITATIONS
361	Cognitive deterioration associated with an expedition in an extreme desert environment. British Journal of Sports Medicine, 2006, 40, 556-560.	3.1	15
362	Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology, 2006, 66, 1447-1450.	1.5	134
363	An investigation of visuospatial memory impairment in children with attention deficit hyperactivity disorder (ADHD), combined type. Psychological Medicine, 2005, 35, 1433-1443.	2.7	40
364	Spatioâ€visual memory of children with specific language impairment: evidence for generalized processing problems. International Journal of Language and Communication Disorders, 2005, 40, 319-332.	0.7	113
365	Fatigue-related impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. Journal of Sleep Research, 2005, 14, 21-27.	1.7	64
366	A manual and automated MRI study of anterior cingulate and orbito-frontal cortices, and caudate nucleus in obsessive-compulsive disorder: comparison with healthy controls and patients with schizophrenia. Psychiatry Research - Neuroimaging, 2005, 138, 99-113.	0.9	121
367	A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Human Psychopharmacology, 2005, 20, 263-273.	0.7	99
368	Neurological and Cognitive Recovery Following Abstinence from Petrol Sniffing. Neuropsychopharmacology, 2005, 30, 1019-1027.	2.8	48
369	Adverse Mental Health Effects of Cannabis Use in Two Indigenous Communities in Arnhem Land, Northern Territory, Australia: Exploratory Study. Australian and New Zealand Journal of Psychiatry, 2005, 39, 612-620.	1.3	16
370	Cognitive Function in Growth Hormone Deficiency and Growth Hormone Replacement. Hormone Research in Paediatrics, 2005, 64, 100-108.	0.8	34
371	Reduced volume of parietal and frontal association areas in patients with schizophrenia characterized by passivity delusions. Psychological Medicine, 2005, 35, 783-789.	2.7	50
372	Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. , 2005, 1, 126-135.		112
373	Repeated Assessment of Cognition in Children and the Measurement of Performance Change. Child Neuropsychology, 2005, 11, 303-310.	0.8	47
374	The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain and Cognition, 2005, 59, 60-70.	0.8	269
375	Examination of the Use of Cognitive Domains in Postoperative Cognitive Dysfunction After Coronary Artery Bypass Graft Surgery. Annals of Thoracic Surgery, 2005, 80, 910-916.	0.7	10
376	Antiretroviral Therapy in HIV Infection. Archives of Neurology, 2004, 61, 1699.	4.9	88
377	<i>APOE</i> influences on neuropsychological function after mild head injury: Within-person comparisons. Neurology, 2004, 63, 2460-2460.	1.5	7
378	Subtle Memory Decline over 12 Months in Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2004, 18, 342-348.	0.7	69

#	Article	IF	CITATIONS
379	Detection of cognitive decline after coronary surgery: a comparison of computerized and conventional tests. British Journal of Anaesthesia, 2004, 92, 814-820.	1.5	72
380	Relationship of behavioural and symptomatic syndromes in schizophrenia to spatial working memory and attentional set-shifting ability. Psychological Medicine, 2004, 34, 693-703.	2.7	63
381	Saccade dysfunction associated with chronic petrol sniffing and lead encephalopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 472-476.	0.9	20
382	Statistical procedures for determining the extent of cognitive change following concussion. British Journal of Sports Medicine, 2004, 38, 273-278.	3.1	61
383	Measuring Exposure to Cannabis use and other Substance use in Remote Aboriginal Populations in Northern Australia: Evaluation of A †Community Epidemiology' Approach using Proxy Respondents. Addiction Research and Theory, 2004, 12, 261-274.	1.2	26
384	Analysis of clinical outcomes following in-hospital adult cardiac arrest. Internal Medicine Journal, 2004, 34, 398-402.	0.5	60
385	Emerging patterns of cannabis and other substance use in Aboriginal communities in Arnhem Land, Northern Territory: a study of two communities. Drug and Alcohol Review, 2004, 23, 381-390.	1.1	52
386	Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus–infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts Clinical Report. Journal of NeuroVirology, 2004, 10, 350-357.	1.0	330
387	Statistical and conceptual issues in defining post-operative cognitive dysfunction. Neuroscience and Biobehavioral Reviews, 2004, 28, 433-440.	2.9	70
388	The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer, 2004, 101, 2143-2144.	2.0	8
389	Development of a statistical approach to classifying treatment response in individual children with ADHD. Human Psychopharmacology, 2004, 19, 445-456.	0.7	54
390	Attention, motor control and motor imagery in schizophrenia: implications for the role of the parietal cortex. Schizophrenia Research, 2004, 70, 241-261.	1.1	126
391	Neurological and cognitive impairment associated with leaded gasoline encephalopathy. Drug and Alcohol Dependence, 2004, 73, 183-188.	1.6	30
392	O2-02-03 Change in plasma amyloid concentration is associated with memory decline in MCI. Neurobiology of Aging, 2004, 25, S34.	1.5	0
393	Internal representation of movement in children with developmental coordination disorder: a mental rotation task. Developmental Medicine and Child Neurology, 2004, 46, 754-9.	1.1	44
394	Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study. Psychiatry Research - Neuroimaging, 2003, 122, 139-152.	0.9	124
395	Procedural learning in children with developmental coordination disorder. Human Movement Science, 2003, 22, 515-526.	0.6	67
396	Saccade and cognitive impairment associated with kava intoxication. Human Psychopharmacology, 2003, 18, 525-533.	0.7	35

#	Article	IF	CITATIONS
397	Attention Deficit Hyperactivity Disorder, Combined Type: Better Executive Function Performance With Longer-Term Psychostimulant Medication. Australian and New Zealand Journal of Psychiatry, 2003, 37, 570-576.	1.3	35
398	Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. Journal of Sleep Research, 2003, 12, 265-274.	1.7	123
399	Abnormalities of motor imagery associated with somatic passivity phenomena in schizophrenia. Schizophrenia Research, 2003, 60, 229-238.	1.1	67
400	The use of Z scores in assessing neuropsychological change after cardiac operations: Reply. Annals of Thoracic Surgery, 2003, 75, 1066-1067.	0.7	0
401	Unilateral pallidotomy for Parkinson's disease disrupts ocular fixation. Journal of Clinical Neuroscience, 2003, 10, 181-185.	0.8	25
402	Significant association between fluctuations in serum urate and high density lipoprotein cholesterol during exhaustive training. British Journal of Sports Medicine, 2003, 37, 370-370.	3.1	2
403	Psychometric issues associated with computerised neuropsychological assessment of concussed athletes. British Journal of Sports Medicine, 2003, 37, 556-559.	3.1	74
404	The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test–retest intervals. Journal of the International Neuropsychological Society, 2003, 9, 419-428.	1.2	368
405	Computerised neuropsychological testing. British Journal of Sports Medicine, 2003, 37, 2-2.	3.1	70
406	Saccade and Cognitive Function in Chronic Kava Users. Neuropsychopharmacology, 2003, 28, 389-396.	2.8	31
407	CogSport: Reliability and Correlation with Conventional Cognitive Tests Used in Postconcussion Medical Evaluations. Clinical Journal of Sport Medicine, 2003, 13, 28-32.	0.9	279
408	Spectrum of Saccade System Function in Alzheimer Disease. Archives of Neurology, 2003, 60, 1272-8.	4.9	74
409	Behavioral Characterization of Mild Cognitive Impairment. Journal of Clinical and Experimental Neuropsychology, 2002, 24, 720-733.	0.8	64
410	Anterior Cingulate Activation During Stroop Task Performance: A PET to MRI Coregistration Study of Individual Patients With Schizophrenia. American Journal of Psychiatry, 2002, 159, 251-254.	4.0	144
411	Selectively Impaired Associative Learning in Older People with Cognitive Decline. Journal of Cognitive Neuroscience, 2002, 14, 484-492.	1.1	33
412	Motor Imagery Training Ameliorates Motor Clumsiness in Children. Journal of Child Neurology, 2002, 17, 491-498.	0.7	130
413	Cognitive Processing in Children Using Cochlear Implants: The Relationship between Visual Memory, Attention, and Executive Functions and Developing Language Skills. Annals of Otology, Rhinology and Laryngology, 2002, 111, 119-126.	0.6	44
414	Impairments of response conflict monitoring and resolution in schizophrenia. Psychological Medicine, 2002, 32, 1251-1260.	2.7	27

#	Article	IF	CITATIONS
415	Paracingulate morphologic differences in males with established schizophrenia: a magnetic resonance imaging morphometric study. Biological Psychiatry, 2002, 52, 15-23.	0.7	151
416	Determining the extent of cognitive change after coronary surgery: a review of statistical procedures. Annals of Thoracic Surgery, 2002, 73, 2005-2011.	0.7	107
417	The cognitive neuropsychiatric approach to investigating the neurobiology of schizophrenia and other disorders. Journal of Psychosomatic Research, 2002, 53, 655-664.	1.2	51
418	Rising cannabis use in Indigenous communities. Medical Journal of Australia, 2002, 177, 395-396.	0.8	19
419	Attention deficit hyperactivity disorder, combined type (ADHD-CT): differences in blood pressure (BP) due to posture and the child report of anxiety. European Child and Adolescent Psychiatry, 2002, 11, 24-30.	2.8	3
420	An Analysis of Systems of Classifying Mild Cognitive Impairment in Older People. Australian and New Zealand Journal of Psychiatry, 2002, 36, 133-140.	1.3	56
421	Characteristics of Parent- and Child-Reported Anxiety in Psychostimulant Medication NaÃ <sup>-</sup> ve, Clinically Referred Children with Attention Deficit Hyperactivity Disorder, Combined Type (ADHD-CT). Australian and New Zealand Journal of Psychiatry, 2002, 36, 234-239.	1.3	21
422	The Neurobehavioural Effects of Kava. Australian and New Zealand Journal of Psychiatry, 2002, 36, 657-662.	1.3	50
423	The neurobehavioural consequences of petrol (gasoline) sniffing. Neuroscience and Biobehavioral Reviews, 2002, 26, 81-89.	2.9	74
424	Cognitive Decline After Coronary Artery Surgery. Archives of Neurology, 2002, 59, 489-490.	4.9	0
425	Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychological Medicine, 2001, 31, 1107-1115.	2.7	151
426	Limitations of early cognitive function testing in the postoperative period. Journal of Cardiothoracic and Vascular Anesthesia, 2001, 15, 671.	0.6	0
427	Possible toxicity and withdrawal seizures in Aboriginal kava drinkers in Arnhem Land, (Australia). South Pacific Journal of Psychology, 2001, 13, 26-33.	0.3	6
428	Computerised cognitive assessment of athletes with sports related head injury. British Journal of Sports Medicine, 2001, 35, 297-302.	3.1	194
429	The ability to execute saccades on the basis of efference copy: impairments in double-step saccade performance in children with developmental co-ordination disorder. Experimental Brain Research, 2001, 136, 73-78.	0.7	57
430	Contextual abnormalities of saccadic inhibition in children with attention deficit hyperactivity disorder. Experimental Brain Research, 2001, 141, 507-518.	0.7	32
431	The Development of a Clinic to Manage Disruptive Behaviour Disorders not Responding to Conventional Psychological and Psychostimulant Treatments. Australasian Psychiatry, 2001, 9, 36-40.	0.4	4
432	Impact of early percutaneous coronary intervention on short- and long-term outcomes in patients with cardiogenic shock after acute myocardial infarction. American Journal of Cardiology, 2001, 87, 633-635.	0.7	11

#	Article	IF	CITATIONS
433	Abnormalities of motor and praxis imagery in children with DCD. Human Movement Science, 2001, 20, 135-159.	0.6	120
434	Computerised cognitive assessment of concussed Australian Rules footballers. British Journal of Sports Medicine, 2001, 35, 354-360.	3.1	133
435	Correspondence. British Journal of Anaesthesia, 2001, 87, 518-524.	1.5	2
436	Goal-directed selective attention and response competition monitoring: Evidence from unilateral parietal and anterior cingulate lesions Neuropsychology, 2000, 14, 16-28.	1.0	25
437	Spatiotemporal distribution of facilitation and inhibition of return arising from the reflexive orienting of covert attention Journal of Experimental Psychology: Human Perception and Performance, 2000, 26, 1733-1745.	0.7	74
438	An optimized method for estimating intracranial volume from magnetic resonance images. Magnetic Resonance in Medicine, 2000, 44, 973-977.	1.9	185
439	Magnetic Resonance Spectroscopy and Schizophrenia: What have we Learnt?. Australian and New Zealand Journal of Psychiatry, 2000, 34, 14-25.	1.3	37
440	The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neuroscience and Biobehavioral Reviews, 2000, 24, 365-374.	2.9	300
441	The voluntary control of motor imagery. Imagined movements in individuals with feigned motor impairment and conversion disorder. Neuropsychologia, 2000, 38, 1251-1260.	0.7	54
442	Issues Associated with the Identification of Cognitive Change Following Coronary Artery Bypass Grafting. Australian and New Zealand Journal of Psychiatry, 2000, 34, 770-784.	1.3	27
443	The effect of an external load on the force and timing components of mentally represented actions. Behavioural Brain Research, 2000, 108, 91-96.	1.2	93
444	Reduced neuropsychological dysfunction using epiaortic echocardiography and the exclusive Y graft. Annals of Thoracic Surgery, 2000, 69, 1431-1438.	0.7	82
445	Goal-directed selective attention and response competition monitoring: evidence from unilateral parietal and anterior cingulate lesions. Neuropsychology, 2000, 14, 16-28.	1.0	17
446	Norms and the Effects of Demographic Variables on a Neuropsychological Battery for Use in Healthy Ageing Australian Populations. Australian and New Zealand Journal of Psychiatry, 1999, 33, 568-575.	1.3	76
447	Behavioral Goals Constrain the Selection of Visual Information. Psychological Science, 1999, 10, 522-525.	1.8	36
448	Deficits in the endogenous control of covert visuospatial attention in children with developmental coordination disorder. Human Movement Science, 1999, 18, 421-442.	0.6	43
449	Asymmetries between dominant and non-dominanthands in real and imagined motor task performance. Neuropsychologia, 1999, 37, 379-384.	0.7	120
450	Facilitation and inhibition arising from the exogenous orienting of covert attention depends on the temporal properties of spatial cues and targets. Neuropsychologia, 1999, 37, 731-744.	0.7	79

#	Article	IF	CITATIONS
451	Abnormalities of imagined motor sequences in children with developmental coordination disorder. Neuropsychologia, 1999, 37, 1317-1324.	0.7	92
452	Covert Orienting of Visual Spatial Attention in Attention Deficit Hyperactivity Disorder Does Comorbidity Make a Difference?. Archives of Clinical Neuropsychology, 1999, 14, 179-189.	0.3	2
453	Attentional modulation of implicit processing of information in spatial neglect. NeuroReport, 1999, 10, 1077-1083.	0.6	25
454	Impairment of olfactory identification in obsessive–compulsive disorder. Psychological Medicine, 1999, 29, 1227-1233.	2.7	64
455	Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychological Medicine, 1999, 29, 527-538.	2.7	316
456	Abnormalities of internally generated saccades in obsessive–compulsive disorder. Psychological Medicine, 1999, 29, 1377-1385.	2.7	47
457	Attention and neuropsychiatric disorders. Current Opinion in Psychiatry, 1999, 12, 339-344.	3.1	9
458	The gap effect and express saccades in the auditory modality. Experimental Brain Research, 1998, 118, 221-229.	0.7	22
459	Cognitive Deficits in Obsessive–Compulsive Disorder on Tests of Frontal–Striatal Function. Biological Psychiatry, 1998, 43, 348-357.	0.7	294
460	Stimulus Relevance in Eliciting Utilisation Behaviour: Case Study in a Patient with a Caudate Lesion. Cognitive Neuropsychiatry, 1998, 3, 287-298.	0.7	12
461	Neurological and cognitive abnormalities associated with chronic petrol sniffing. Brain, 1998, 121, 1903-1917.	3.7	87
462	Neuropsychological Deficits in Obsessive-compulsive Disorder. Archives of General Psychiatry, 1998, 55, 415.	13.8	286
463	Investigating form and colour perception in blindsight using an interference task. NeuroReport, 1998, 9, 2919-2925.	0.6	25
464	Saccadic and attentional abnormalities in patients with schizophrenia. Psychological Medicine, 1998, 28, 1091-1100.	2.7	64
465	Inhibitory processes in covert orienting in patients with Alzheimer's disease Neuropsychology, 1998, 12, 225-241.	1.0	61
466	Pet correlational studies of auditory stimulation and auditory hallucinations in schizophrenia patients. Schizophrenia Research, 1997, 24, 164.	1.1	0
467	Neuropsychological function in young patients with unipolar major depression. Psychological Medicine, 1997, 27, 1277-1285.	2.7	231
468	Object-based visual attention in luminance increment detection?. Neuropsychologia, 1997, 35, 843-853.	0.7	9

#	Article	IF	CITATIONS
469	Manipulating the disengage operation of covert visual spatial attention. Perception & Psychophysics, 1997, 59, 500-508.	2.3	11
470	Collection and normal levels of the amyloid precursor protein in plasma. Annals of Neurology, 1997, 41, 121-124.	2.8	21
471	Covert orienting of visuospatial attention in children with developmental coordination disorder. Developmental Medicine and Child Neurology, 1997, 39, 736-745.	1.1	68
472	Deficits in the endogenous redirection of covert visual attention in chronic schizophrenia. Neuropsychologia, 1996, 34, 1079-1084.	0.7	44
473	An attentional grasp reflex in patients with Alzheimer's disease. Neuropsychologia, 1995, 33, 689-701.	0.7	32
474	Asymmetries in the covert orienting of visual spatial attention in schizophrenia. Neuropsychologia, 1995, 33, 1205-1223.	0.7	109
475	Asymmetries in the covert orienting of visual spatial attention to spatial and non-spatial cues in Alzheimer's disease. Brain, 1995, 118, 1421-1435.	3.7	44
476	Petrol sniffing down the track. Medical Journal of Australia, 1994, 160, 729-730.	0.8	6
477	Selective impairment of express saccade generation in patients with schizophrenia. Experimental Brain Research, 1993, 97, 343-8.	0.7	28
478	Validation of a Clinical Antisaccadic Eye Movement Test in the Assessment of Dementia. Archives of Neurology, 1991, 48, 644-648.	4.9	111
479	Norms and the Effects of Demographic Variables on a Neuropsychological Battery for Use in Healthy Ageing Australian Populations. , 0, .		12
480	Issues Associated with the Identification of Cognitive Change Following Coronary Artery Bypass Grafting. , 0, .		4
481	Adverse Mental Health Effects of Cannabis Use in Two Indigenous Communities in Arnhem Land, Northern Territory, Australia: Exploratory Study. , 0, .		5